{
  "id": "64184483690f196b51000038",
  "type": "summary",
  "question": "What is the reason for N-acetylgalactosamine (GalNAc) conjugation of siRNAs?",
  "ideal_answer": "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28988716",
    "http://www.ncbi.nlm.nih.gov/pubmed/30820542",
    "http://www.ncbi.nlm.nih.gov/pubmed/29792572",
    "http://www.ncbi.nlm.nih.gov/pubmed/32771924",
    "http://www.ncbi.nlm.nih.gov/pubmed/35867041",
    "http://www.ncbi.nlm.nih.gov/pubmed/36250252",
    "http://www.ncbi.nlm.nih.gov/pubmed/36345805",
    "http://www.ncbi.nlm.nih.gov/pubmed/25730476",
    "http://www.ncbi.nlm.nih.gov/pubmed/35505960",
    "http://www.ncbi.nlm.nih.gov/pubmed/34413198",
    "http://www.ncbi.nlm.nih.gov/pubmed/34154993",
    "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
    "http://www.ncbi.nlm.nih.gov/pubmed/25434769",
    "http://www.ncbi.nlm.nih.gov/pubmed/26011654",
    "http://www.ncbi.nlm.nih.gov/pubmed/28129130",
    "http://www.ncbi.nlm.nih.gov/pubmed/34091052",
    "http://www.ncbi.nlm.nih.gov/pubmed/25786782",
    "http://www.ncbi.nlm.nih.gov/pubmed/32170309",
    "http://www.ncbi.nlm.nih.gov/pubmed/31279228",
    "http://www.ncbi.nlm.nih.gov/pubmed/36281788",
    "http://www.ncbi.nlm.nih.gov/pubmed/29069408",
    "http://www.ncbi.nlm.nih.gov/pubmed/35997897"
  ],
  "snippets": [
    {
      "text": "Two decades after the discovery of the RNA interference mechanism, the first siRNA drugs received approval for clinical use by the US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35997897",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35867041",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patisiran (hereditary transthyretin-mediated amyloidosis) was the first licensed siRNA, followed by givosiran (acute hepatic porphyria), lumasiran (primary hyperoxaluria type 1) and inclisiran (familial hypercholesterolaemia), which all use N-acetylgalactosamine (GalNAc) linkage for effective liver-directed delivery. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250252",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to N-acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34154993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786782",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hypercholesterolemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36281788",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "N-Acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) are a leading RNA interference (RNAi) platform allowing targeted inhibition of disease-causing genes in hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34091052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "GalNAc binds the asialoglycoprotein receptor (ASGPR) that is highly expressed on hepatocytes and exploits this scavenger receptor to deliver siRNA across the plasma membrane by endocytosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35505960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asialoglycoprotein receptor (ASGPR) mediated delivery of triantennary N-acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) to hepatocytes is a promising paradigm for RNAi therapeutics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25730476",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786782",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35867041",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conjugation of triantennary N-acetyl galactosamine (GalNAc) to oligonucleotide therapeutics results in marked improvement in potency for reducing gene targets expressed in hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26011654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The conjugation of ASOs to a receptor ligand can dramatically increase their entry into certain cells and tissues, as demonstrated by the implementation of N-acetylgalactosamine (GalNAc)-conjugated ASOs for Asialoglycoprotein Receptor (ASGR)-mediated uptake into liver hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069408",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In pre-clinical models, attachment of a triantennary N-acetylgalactosamine (GalNAc) ligand to an siRNA mediates hepatocyte uptake via the asialoglycoprotein receptor enabling RNAi-mediated gene silencing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The development of GalNAc-siRNA conjugates, in which a synthetic triantennary N-acetylgalactosamine-based ligand is conjugated to chemically modified siRNA, has enabled efficient, ASGPR-mediated delivery to hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988716",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Moreover, we found that conjugation of \u03b1-N-acetylgalactosamine (GalNAc) with two lncRNA-directed siRNAs allows for direct liver cell targeting of this lncRNA and functional enhanced uptake of cholesterol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31279228",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Foremost of these has been the development of N-acetylgalactosamine (GalNAc) siRNA conjugates for delivery to liver.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792572",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32771924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conjugation of small interfering RNA (siRNA) to tris N-acetylgalactosamine [(GalNAc)3] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Exposure to 2'-F-monomer metabolites was low and transien",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30820542",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "d to a trivalent N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Sense and antisense strands of the parent duplex were syn",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32170309",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc ar",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ine (GalNAc) moieties to ASOs or siRNAs facilitates receptor-mediated uptake by the asialoglycoprotein receptor. In summary, ATTR is a progressive dis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36345805",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32771924",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}